Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Enzastaurin and fragile histidine triad (FHIT)-increasing agents for the treatment of pulmonary hypertension

Enzastaurin and fragile histidine triad (FHIT)-increasing agents for the treatment of pulmonary hypertension

US Patent 11413280 · Granted Aug 16, 2022

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Protein and gene biomarkers for rejection of organ transplants2023
Biomarkers for use in prognosis of mortality in critically ill patients2023
Methods for diagnosis of bacterial and viral infections2022
Infiltrating immune cell proportions predict anti-TNF response in colon biopsies2022
Methods for diagnosis of tuberculosis2021
Biomarkers for use in prognosis of mortality in critically ill patients2020
Methods for diagnosis of sepsis2020
Biomarkers for use in prognosis of mortality in critically ill patients2019
Protein and gene biomarkers for rejection of organ transplants2017
Use of FK506 for the treatment of pulmonary arterial hypertension2016